Literature DB >> 21501627

Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.

Maarten van den Buuse1, Emma Ruimschotel, Sally Martin, Victoria B Risbrough, Adam L Halberstadt.   

Abstract

Serotonin-1A (5-HT(1A)) receptors may play a role in schizophrenia and the effects of certain antipsychotic drugs. However, the mechanism of interaction of 5-HT(1A) receptors with brain systems involved in schizophrenia, remains unclear. Here we show that 5-HT(1A) receptor knockout mice display enhanced locomotor hyperactivity to acute treatment with amphetamine, a widely used animal model of hyperdopaminergic mechanisms in psychosis. In contrast, the effect of MK-801 on locomotor activity, modeling NMDA receptor hypoactivity, was unchanged in the knockouts. The effect of the hallucinogen 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) was markedly reduced in 5-HT(1A) receptor knockout mice. There were no changes in apomorphine-induced disruption of PPI, a model of sensory gating deficits seen in schizophrenia. Similarly, there were no major changes in density of dopamine transporters (DAT) or dopamine D(1) or D(2) receptors which could explain the behavioural changes observed in 5-HT(1A) receptor knockout mice. These results extend our insight into the possible role of these receptors in aspects of schizophrenia. As also suggested by previous studies using agonist and antagonist drugs, 5-HT(1A) receptors may play an important role in hallucinations and to modulate dopaminergic activity in the brain.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21501627      PMCID: PMC3866100          DOI: 10.1016/j.neuropharm.2011.04.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  42 in total

Review 1.  Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

Authors:  M J Millan
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

2.  The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.

Authors:  J Ichikawa; H Y Meltzer
Journal:  Brain Res       Date:  2000-03-10       Impact factor: 3.252

3.  The presynaptic component of the serotonergic system is required for clozapine's efficacy.

Authors:  Prem N Yadav; Atheir I Abbas; Martilias S Farrell; Vincent Setola; Noah Sciaky; Xi-Ping Huang; Wesley K Kroeze; LaTasha K Crawford; David A Piel; Michael J Keiser; John J Irwin; Brian K Shoichet; Evan S Deneris; Jay Gingrich; Sheryl G Beck; Bryan L Roth
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

4.  Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition.

Authors:  S C Dulawa; C Gross; K L Stark; R Hen; M A Geyer
Journal:  Neuropsychopharmacology       Date:  2000-06       Impact factor: 7.853

Review 5.  Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.

Authors:  M A Geyer; K Krebs-Thomson; D L Braff; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

6.  Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.

Authors:  Adam L Halberstadt; Liselore Koedood; Susan B Powell; Mark A Geyer
Journal:  J Psychopharmacol       Date:  2010-12-08       Impact factor: 4.153

7.  Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.

Authors:  María Cecilia Scorza; Anna Castañé; Analía Bortolozzi; Francesc Artigas
Journal:  Neuropharmacology       Date:  2010-04-20       Impact factor: 5.250

8.  Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation.

Authors:  Maarten van den Buuse; Lena Wischhof; Ruo Xi Lee; Sally Martin; Tim Karl
Journal:  Int J Neuropsychopharmacol       Date:  2009-04-29       Impact factor: 5.176

9.  The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study.

Authors:  Carolina Chavez; Marianne Hollaus; Elizabeth Scarr; Geoff Pavey; Andrea Gogos; Maarten van den Buuse
Journal:  Brain Res       Date:  2010-01-14       Impact factor: 3.252

10.  Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.

Authors:  Andrea Gogos; Perrin Kwek; Carolina Chavez; Maarten van den Buuse
Journal:  J Pharmacol Exp Ther       Date:  2009-12-30       Impact factor: 4.030

View more
  14 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

2.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

3.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

4.  Disturbed Prefrontal Cortex Activity in the Absence of Schizophrenia-Like Behavioral Dysfunction in Arc/Arg3.1 Deficient Mice.

Authors:  Xiaoyan Gao; Jasper Grendel; Mary Muhia; Sergio Castro-Gomez; Ute Süsens; Dirk Isbrandt; Matthias Kneussel; Dietmar Kuhl; Ora Ohana
Journal:  J Neurosci       Date:  2019-09-05       Impact factor: 6.167

5.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

Review 6.  Effect of Hallucinogens on Unconditioned Behavior.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2018

7.  (2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice.

Authors:  Deborah Rudin; John D McCorvy; Grant C Glatfelter; Dino Luethi; Dániel Szöllősi; Tea Ljubišić; Pierce V Kavanagh; Geraldine Dowling; Marion Holy; Kathrin Jaentsch; Donna Walther; Simon D Brandt; Thomas Stockner; Michael H Baumann; Adam L Halberstadt; Harald H Sitte
Journal:  Neuropsychopharmacology       Date:  2021-11-08       Impact factor: 8.294

Review 8.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

9.  Altered exploration and sensorimotor gating of the chakragati mouse model of schizophrenia.

Authors:  Jared W Young; Anil Ratty; Gavin S Dawe; Mark A Geyer
Journal:  Behav Neurosci       Date:  2014-04-07       Impact factor: 1.912

Review 10.  Serotonergic hallucinogens as translational models relevant to schizophrenia.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Int J Neuropsychopharmacol       Date:  2013-08-13       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.